Hypertension – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hypertension – Pipeline Review, H2 2016’, provides an overview of the Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypertension

The report reviews pipeline therapeutics for Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypertension therapeutics and enlists all their major and minor projects

The report assesses Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypertension

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A1M Pharma AB

AbbVie Inc

Actelion Ltd

Afferent Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Anacor Pharmaceuticals Inc

AnGes MG Inc

APT Therapeutics Inc

Arena Pharmaceuticals Inc

Ascendis Pharma A/S

Asklepion Pharmaceuticals LLC

AVEO Pharmaceuticals Inc

Bayer AG

Bial – Portela & Ca SA

Biolab Farmaceutica Ltda

BioRestorative Therapies Inc

Boryung Pharmaceutical Co Ltd

Cellceutix Corp

Celsion Corp

Celtaxsys Inc

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Complexa Inc

Conatus Pharmaceuticals Inc

Corion Biotech Srl

Cumberland Pharmaceuticals Inc

Cytokinetics Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

DiaMedica Inc

Eli Lilly and Company

Esperion Therapeutics Inc

F. Hoffmann-La Roche Ltd

Ferring International Center SA

Galectin Therapeutics Inc

Genextra Spa

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenveigh Medical LLC

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

HitGen LTD

Innopharmax Inc

Insmed Inc

INVENT Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

JW Pharmaceutical Corp

Kowa Company Ltd

Leading BioSciences Inc

Lee's Pharmaceutical Holdings Ltd

Les Laboratoires Servier SAS

LFB SA

LG Life Science LTD

LinXis BV

Liquidia Technologies Inc

Lotus Pharmaceutical Co Ltd

MannKind Corp

Mast Therapeutics Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

miRagen Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Morphogen-IX Ltd

Neurim Pharmaceuticals Ltd

Nippon Kayaku Co Ltd

Nippon Shinyaku Co Ltd

Novartis AG

Noxamet Ltd

Omeros Corp

Peloton Therapeutics Inc

Pfizer Inc

PhaseBio Pharmaceuticals Inc

Pluristem Therapeutics Inc

Polyphor Ltd

Proteo Inc

Pulmokine Inc

Quantum Genomics SA

Reata Pharmaceuticals Inc

RedHill Biopharma Ltd

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

Sanofi

Selten Pharma Inc

Serodus ASA

Shanghai Pharmaceutical Co Ltd

Silence Therapeutics Plc

Simcere Pharmaceutical Group

SteadyMed Therapeutics Inc

Suda Ltd

Sumitomo Dainippon Pharma Co Ltd

Takeda Pharmaceutical Company Ltd

The Medicines Company

Theravance Biopharma Inc

Toray Industries Inc

Torrent Pharmaceuticals Ltd

TSH Biopharm Corporation Ltd

United Therapeutics Corp

VBS Pharmaceuticals

Vectura Group Plc

VG Life Sciences Inc

Vicore Pharma AB

XORTX Pharma Corp

XuanZhu Pharma Co Ltd

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Hypertension Overview 8

Therapeutics Development 9

Hypertension - Therapeutics under Development by Companies 11

Hypertension - Therapeutics under Investigation by Universities/Institutes 19

Hypertension - Pipeline Products Glance 21

Hypertension - Products under Development by Companies 24

Hypertension - Products under Investigation by Universities/Institutes 37

Hypertension - Companies Involved in Therapeutics Development 39

Hypertension - Therapeutics Assessment 146

Drug Profiles 168

Hypertension - Dormant Projects 486

Hypertension - Discontinued Products 512

Hypertension - Product Development Milestones 515

Appendix 527

List of Tables

List of Tables

Number of Products under Development for Hypertension, H2 2016 32

Number of Products under Development for Hypertension – Comparative Analysis, H2 2016 33

Number of Products under Development by Companies, H2 2016 34

Number of Products under Development by Companies, H2 2016 (Contd..1) 35

Number of Products under Development by Companies, H2 2016 (Contd..2) 36

Number of Products under Development by Companies, H2 2016 (Contd..3) 37

Number of Products under Development by Companies, H2 2016 (Contd..4) 38

Number of Products under Development by Companies, H2 2016 (Contd..5) 39

Number of Products under Development by Companies, H2 2016 (Contd..6) 40

Number of Products under Development by Companies, H2 2016 (Contd..7) 41

Number of Products under Investigation by Universities/Institutes, H2 2016 43

Comparative Analysis by Late Stage Development, H2 2016 44

Comparative Analysis by Clinical Stage Development, H2 2016 45

Comparative Analysis by Early Stage Development, H2 2016 46

Products under Development by Companies, H2 2016 47

Products under Development by Companies, H2 2016 (Contd..1) 48

Products under Development by Companies, H2 2016 (Contd..2) 49

Products under Development by Companies, H2 2016 (Contd..3) 50

Products under Development by Companies, H2 2016 (Contd..4) 51

Products under Development by Companies, H2 2016 (Contd..5) 52

Products under Development by Companies, H2 2016 (Contd..6) 53

Products under Development by Companies, H2 2016 (Contd..7) 54

Products under Development by Companies, H2 2016 (Contd..8) 55

Products under Development by Companies, H2 2016 (Contd..9) 56

Products under Development by Companies, H2 2016 (Contd..10) 57

Products under Development by Companies, H2 2016 (Contd..11) 58

Products under Development by Companies, H2 2016 (Contd..12) 59

Products under Investigation by Universities/Institutes, H2 2016 60

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 61

Hypertension – Pipeline by A1M Pharma AB, H2 2016 62

Hypertension – Pipeline by AbbVie Inc, H2 2016 63

Hypertension – Pipeline by Actelion Ltd, H2 2016 64

Hypertension – Pipeline by Afferent Pharmaceuticals Inc, H2 2016 65

Hypertension – Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 66

Hypertension – Pipeline by Anacor Pharmaceuticals Inc, H2 2016 67

Hypertension – Pipeline by AnGes MG Inc, H2 2016 68

Hypertension – Pipeline by APT Therapeutics Inc, H2 2016 69

Hypertension – Pipeline by Arena Pharmaceuticals Inc, H2 2016 70

Hypertension – Pipeline by Ascendis Pharma A/S, H2 2016 71

Hypertension – Pipeline by Asklepion Pharmaceuticals LLC, H2 2016 72

Hypertension – Pipeline by AVEO Pharmaceuticals Inc, H2 2016 73

Hypertension – Pipeline by Bayer AG, H2 2016 74

Hypertension – Pipeline by Bial – Portela & Ca SA, H2 2016 75

Hypertension – Pipeline by Biolab Farmaceutica Ltda, H2 2016 76

Hypertension – Pipeline by BioRestorative Therapies Inc, H2 2016 77

Hypertension – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 78

Hypertension – Pipeline by Cellceutix Corp, H2 2016 79

Hypertension – Pipeline by Celsion Corp, H2 2016 80

Hypertension – Pipeline by Celtaxsys Inc, H2 2016 81

Hypertension – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 82

Hypertension – Pipeline by CJ HealthCare Corp, H2 2016 83

Hypertension – Pipeline by Complexa Inc, H2 2016 84

Hypertension – Pipeline by Conatus Pharmaceuticals Inc, H2 2016 85

Hypertension – Pipeline by Corion Biotech Srl, H2 2016 86

Hypertension – Pipeline by Cumberland Pharmaceuticals Inc, H2 2016 87

Hypertension – Pipeline by Cytokinetics Inc, H2 2016 88

Hypertension – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 89

Hypertension – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 90

Hypertension – Pipeline by DiaMedica Inc, H2 2016 91

Hypertension – Pipeline by Eli Lilly and Company, H2 2016 92

Hypertension – Pipeline by Esperion Therapeutics Inc, H2 2016 93

Hypertension – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 94

Hypertension – Pipeline by Ferring International Center SA, H2 2016 95

Hypertension – Pipeline by Galectin Therapeutics Inc, H2 2016 96

Hypertension – Pipeline by Genextra Spa, H2 2016 97

Hypertension – Pipeline by Gilead Sciences Inc, H2 2016 98

Hypertension – Pipeline by GlaxoSmithKline Plc, H2 2016 99

Hypertension – Pipeline by Glenveigh Medical LLC, H2 2016 100

Hypertension – Pipeline by HanAll Biopharma Co Ltd, H2 2016 101

Hypertension – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 102

Hypertension – Pipeline by HitGen LTD, H2 2016 103

Hypertension – Pipeline by Innopharmax Inc, H2 2016 104

Hypertension – Pipeline by Insmed Inc, H2 2016 105

Hypertension – Pipeline by INVENT Pharmaceuticals Inc, H2 2016 106

Hypertension – Pipeline by Ionis Pharmaceuticals Inc, H2 2016 107

Hypertension – Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 108

Hypertension – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 109

Hypertension – Pipeline by Johnson & Johnson, H2 2016 110

Hypertension – Pipeline by JW Pharmaceutical Corp, H2 2016 111

Hypertension – Pipeline by Kowa Company Ltd, H2 2016 112

Hypertension – Pipeline by Leading BioSciences Inc, H2 2016 113

Hypertension – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2016 114

Hypertension – Pipeline by Les Laboratoires Servier SAS, H2 2016 115

Hypertension – Pipeline by LFB SA, H2 2016 116

Hypertension – Pipeline by LG Life Science LTD, H2 2016 117

Hypertension – Pipeline by LinXis BV, H2 2016 118

Hypertension – Pipeline by Liquidia Technologies Inc, H2 2016 119

Hypertension – Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016 120

Hypertension – Pipeline by MannKind Corp, H2 2016 121

Hypertension – Pipeline by Mast Therapeutics Inc, H2 2016 122

Hypertension – Pipeline by Merck & Co Inc, H2 2016 123

Hypertension – Pipeline by Mezzion Pharma Co Ltd, H2 2016 124

Hypertension – Pipeline by miRagen Therapeutics Inc, H2 2016 125

Hypertension – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 126

Hypertension – Pipeline by Morphogen-IX Ltd, H2 2016 127

Hypertension – Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 128

Hypertension – Pipeline by Nippon Kayaku Co Ltd, H2 2016 129

Hypertension – Pipeline by Nippon Shinyaku Co Ltd, H2 2016 130

Hypertension – Pipeline by Novartis AG, H2 2016 131

Hypertension – Pipeline by Noxamet Ltd, H2 2016 132

Hypertension – Pipeline by Omeros Corp, H2 2016 133

Hypertension – Pipeline by Peloton Therapeutics Inc, H2 2016 134

Hypertension – Pipeline by Pfizer Inc, H2 2016 135

Hypertension – Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016 136

Hypertension – Pipeline by Pluristem Therapeutics Inc, H2 2016 137

Hypertension – Pipeline by Polyphor Ltd, H2 2016 138

Hypertension – Pipeline by Proteo Inc, H2 2016 139

Hypertension – Pipeline by Pulmokine Inc, H2 2016 140

Hypertension – Pipeline by Quantum Genomics SA, H2 2016 141

Hypertension – Pipeline by Reata Pharmaceuticals Inc, H2 2016 142

Hypertension – Pipeline by RedHill Biopharma Ltd, H2 2016 143

Hypertension – Pipeline by Respira Therapeutics Inc, H2 2016 144

Hypertension – Pipeline by Reviva Pharmaceuticals Inc, H2 2016 145

Hypertension – Pipeline by Sanofi, H2 2016 146

Hypertension – Pipeline by Selten Pharma Inc, H2 2016 147

Hypertension – Pipeline by Serodus ASA, H2 2016 148

Hypertension – Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016 149

Hypertension – Pipeline by Silence Therapeutics Plc, H2 2016 150

Hypertension – Pipeline by Simcere Pharmaceutical Group, H2 2016 151

Hypertension – Pipeline by SteadyMed Therapeutics Inc, H2 2016 152

Hypertension – Pipeline by Suda Ltd, H2 2016 153

Hypertension – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 154

Hypertension – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 155

Hypertension – Pipeline by The Medicines Company, H2 2016 156

Hypertension – Pipeline by Theravance Biopharma Inc, H2 2016 157

Hypertension – Pipeline by Toray Industries Inc, H2 2016 158

Hypertension – Pipeline by Torrent Pharmaceuticals Ltd, H2 2016 159

Hypertension – Pipeline by TSH Biopharm Corporation Ltd, H2 2016 160

Hypertension – Pipeline by United Therapeutics Corp, H2 2016 161

Hypertension – Pipeline by VBS Pharmaceuticals, H2 2016 162

Hypertension – Pipeline by Vectura Group Plc, H2 2016 163

Hypertension – Pipeline by VG Life Sciences Inc, H2 2016 164

Hypertension – Pipeline by Vicore Pharma AB, H2 2016 165

Hypertension – Pipeline by XORTX Pharma Corp, H2 2016 166

Hypertension – Pipeline by XuanZhu Pharma Co Ltd, H2 2016 167

Hypertension – Pipeline by Yuhan Corp, H2 2016 168

Assessment by Monotherapy Products, H2 2016 169

Assessment by Combination Products, H2 2016 170

Number of Products by Stage and Target, H2 2016 172

Number of Products by Stage and Mechanism of Action, H2 2016 180

Number of Products by Stage and Route of Administration, H2 2016 188

Number of Products by Stage and Molecule Type, H2 2016 190

Hypertension – Dormant Projects, H2 2016 509

Hypertension – Dormant Projects (Contd..1), H2 2016 510

Hypertension – Dormant Projects (Contd..2), H2 2016 511

Hypertension – Dormant Projects (Contd..3), H2 2016 512

Hypertension – Dormant Projects (Contd..4), H2 2016 513

Hypertension – Dormant Projects (Contd..5), H2 2016 514

Hypertension – Dormant Projects (Contd..6), H2 2016 515

Hypertension – Dormant Projects (Contd..7), H2 2016 516

Hypertension – Dormant Projects (Contd..8), H2 2016 517

Hypertension – Dormant Projects (Contd..9), H2 2016 518

Hypertension – Dormant Projects (Contd..10), H2 2016 519

Hypertension – Dormant Projects (Contd..11), H2 2016 520

Hypertension – Dormant Projects (Contd..12), H2 2016 521

Hypertension – Dormant Projects (Contd..13), H2 2016 522

Hypertension – Dormant Projects (Contd..14), H2 2016 523

Hypertension – Dormant Projects (Contd..15), H2 2016 524

Hypertension – Dormant Projects (Contd..16), H2 2016 525

Hypertension – Dormant Projects (Contd..17), H2 2016 526

Hypertension – Dormant Projects (Contd..18), H2 2016 527

Hypertension – Dormant Projects (Contd..19), H2 2016 528

Hypertension – Dormant Projects (Contd..20), H2 2016 529

Hypertension – Dormant Projects (Contd..21), H2 2016 530

Hypertension – Dormant Projects (Contd..22), H2 2016 531

Hypertension – Dormant Projects (Contd..23), H2 2016 532

Hypertension – Dormant Projects (Contd..24), H2 2016 533

Hypertension – Dormant Projects (Contd..25), H2 2016 534

Hypertension – Discontinued Products, H2 2016 535

Hypertension – Discontinued Products (Contd..1), H2 2016 536

Hypertension – Discontinued Products (Contd..2), H2 2016 537

List of Figures

List of Figures

Number of Products under Development for Hypertension, H2 2016 32

Number of Products under Development for Hypertension – Comparative Analysis, H2 2016 33

Number of Products under Development by Companies, H2 2016 34

Number of Products under Investigation by Universities/Institutes, H2 2016 42

Comparative Analysis by Late Stage Development, H2 2016 44

Comparative Analysis by Clinical Stage Development, H2 2016 45

Comparative Analysis by Early Stage Products, H2 2016 46

Assessment by Monotherapy Products, H2 2016 169

Assessment by Combination Products, H2 2016 170

Number of Products by Top 10 Targets, H2 2016 171

Number of Products by Stage and Top 10 Targets, H2 2016 171

Number of Products by Top 10 Mechanism of Actions, H2 2016 179

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 179

Number of Products by Top 10 Routes of Administration, H2 2016 187

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 187

Number of Products by Top 10 Molecule Types, H2 2016 189

Number of Products by Stage and Top 10 Molecule Types, H2 2016 189

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports